BioMark Diagnostics Inc. BMKDF
OTC PK
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | 0.00% | 2.00% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 0.00% | 2.00% | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | 0.00% | 2.00% | |||
| SG&A Expenses | 46.09% | -49.07% | |||
| Depreciation & Amortization | 82.58% | -60.87% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 16.10% | -30.59% | |||
| Operating Income | -16.42% | 31.03% | |||
| Income Before Tax | -81.02% | 46.70% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -81.02% | 46.70% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -81.02% | 46.70% | |||
| EBIT | -16.42% | 31.03% | |||
| EBITDA | -16.57% | 31.30% | |||
| EPS Basic | -78.57% | 46.15% | |||
| Normalized Basic EPS | -66.67% | 43.75% | |||
| EPS Diluted | -78.57% | 46.15% | |||
| Normalized Diluted EPS | -66.67% | 43.75% | |||
| Average Basic Shares Outstanding | 1.21% | 0.00% | |||
| Average Diluted Shares Outstanding | 1.21% | 0.00% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||